Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Geriatric Oncology Clear all
Recruiting Not applicable Interventional

Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly

NCT06309225
View directory record Official record
Conditions
Oropharynx Cancer, Frailty
Interventions
Modified dose and fields intensity modulated radiotherapy
Radiation
Lead sponsor
Omar Mahmoud
Other
Eligibility
65 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jul 23, 2026, 11:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management

NCT07242118
View directory record Official record
Conditions
Breast Cancer Female
Interventions
SABR
Radiation
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 23, 2026, 11:26 AM EDT
Withdrawn Phase 2 Interventional

Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy

NCT04223661
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide Pill, Dexamethasone, Daratumumab
Drug
Lead sponsor
Attaya Suvannasankha
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Jul 23, 2026, 11:26 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35

NCT00161226
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Levonorgestrel intrauterine system
Device
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Jul 23, 2026, 11:26 AM EDT
Completed No phase listed Observational

Finding Predictors of Side Effects to Chemoradiation Treatment in Elderly Patients With Head and Neck Cancer

NCT01688323
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Collect Blood and Survey Instruments
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Jul 23, 2026, 11:26 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Pimasertib in Hematological Malignancies

NCT00957580
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Hematologic Neoplasms
Interventions
Pimasertib
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia

NCT00607997
View directory record Official record
Conditions
Leukemia, Acute Disease, Acute Myeloid Leukemia, Nonlymphocytic Leukemia, Myelodysplastic Syndromes
Interventions
vosaroxin
Drug
Lead sponsor
Sunesis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation

NCT01607879
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of care ADT + (HMB + arginine + glutamine), Standard of care ADT
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
60 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Jul 23, 2026, 11:26 AM EDT
Recruiting Phase 1 Interventional

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

NCT07089641
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Glioblastoma
Interventions
Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Surgical Procedure
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 11:26 AM EDT
Recruiting Not applicable Interventional

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

NCT06824818
View directory record Official record
Conditions
Elderly, Prostate Cancer
Interventions
LHRH Agonist Therapy Discontinuation
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
70 Years and older · Male only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

NCT03226418
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions
Cytarabine, Decitabine, Idarubicin, Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine, Quality-of-Life Assessment, Questionnaire Administration, Azacitidine, Venetoclax, glasdegib
Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
60 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 23, 2026, 11:26 AM EDT
Active, not recruiting Not applicable Interventional

Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With Cancer

NCT02517034
View directory record Official record
Conditions
Solid Neoplasm
Interventions
Comprehensive Geriatric Assessment, Quality-of-Life Assessment, Questionnaire Administration, Survey Administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
5
States / cities
Duarte, California • Lancaster, California • Rancho Cucamonga, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 2 Interventional

Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

NCT01149850
View directory record Official record
Conditions
Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma
Interventions
bevacizumab, temozolomide, laboratory biomarker analysis, immunohistochemistry staining method, microarray analysis, DNA methylation analysis
Biological · Drug · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
70 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 11:26 AM EDT
Not listed Phase 3 Interventional

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission

NCT00454168
View directory record Official record
Conditions
Leukemia
Interventions
PR1 leukemia peptide vaccine, sargramostim, placebo
Biological · Other
Lead sponsor
The Vaccine Company
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • South San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Jul 23, 2026, 11:26 AM EDT
Recruiting Phase 2 Interventional

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

NCT05952024
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Acalabrutinib, Rituximab
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
65 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
14
States / cities
Berkeley, California • La Jolla, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

NCT01358734
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
Interventions
Azacitidine, Lenalidomide, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
65 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Jul 23, 2026, 11:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer

NCT00351039
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Bevacizumab, Erlotinib, Pemetrexed
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
70 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Jul 23, 2026, 11:26 AM EDT
Active, not recruiting Not applicable Interventional

Care Planning Framework in Advanced Cancer (ABC123)

NCT05408507
View directory record Official record
Conditions
Advanced Cancer
Interventions
ABC123 Framework
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 23, 2026, 11:26 AM EDT
Completed No phase listed Observational

Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NCT01026467
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cisplatin, carboplatin, questionnaire administration
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Syracuse, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

NCT02056392
View directory record Official record
Conditions
Solid Tumours
Interventions
Selumetinib, Moxifloxacin, selumetinib placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2015 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Not applicable Interventional

Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma

NCT04100044
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Exercise Counseling, Exercise Intervention, Questionnaire administration, Quality-of-Life Assessment
Other · Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
65 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Not applicable Interventional

A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer

NCT00984321
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Lymphoma Cancer, Gynecological Cancers
Interventions
group intervention and questionnaires, individual phone intervention and questionnaires, expressive writing (arm will not be include in the randomization)
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
70 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients

NCT00590187
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Sapacitabine, Arm A, Sapacitabine, Arm B, Sapacitabine, Arm C, Sapacitabine, Arm D, sapacitabine, Arm E, sapacitabine, Arm F, Sapacitabine, Arm G, Sapacitabine, Arm H, Sapacitabine, Arm I
Drug
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jul 23, 2026, 11:26 AM EDT
Completed Phase 1 Interventional

Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia

NCT01130662
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
combination therapy using decitabine and midostaurin
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Jul 23, 2026, 11:26 AM EDT